Polyrizon’s NASARIX tissue scaffold passed key preclinical biocompatibility testing with no adverse cytotoxic or sensitization findings. Shares climbed 1.3% on July 2 as investors anticipated faster progression toward regulatory submission and clinical evaluation.
On July 2, Polyrizon announced that its NASARIX tissue scaffold successfully passed comprehensive preclinical biocompatibility tests, demonstrating no cytotoxicity, sensitization or irritation responses. This validation addresses a critical safety requirement for advancing the bioscaffold toward regulatory review.
Polyrizon shares rose 1.3% on the day of the announcement as investors reacted positively to the reduced development risk and the clearer path toward clinical trials. Trading volume also ticked higher, indicating increased investor interest in the company’s pipeline.
With biocompatibility data secured, Polyrizon is positioned to compile its safety dossier for formal regulatory submissions and to design first-in-human studies. This milestone could accelerate timelines for investigational device applications and subsequent clinical evaluation phases.
